Following our series of posts in biosimilars and immunogenicity testing, a recent paper by Korea company Celltrion describes the characterisation of Remsina®, the first mAb biosimilar (for Remicade® – infliximab) approved in Europe. In this study, ELISA arrays for conformational studies were used for the Higher Order Structure characterisation and compatibility analysis.